Author

J. D. Kratz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. A. Gillette· 2 shared A. K. DeZeeuw· 2 shared C. A. Pasch· 2 shared D. A. Deming· 2 shared K. A. Johnson· 2 shared L. Clipson· 2 shared M. C. Skala· 2 shared A. H. Yeung· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. A. Gillette

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma

M. Nukaya, C. Cafferty, K. Zahed, I. Yun, D. P. Al-Adra, N. A. Kazim, A. R. Farghli, M. Chan, J. D. Kratz, M. E. Berres, A. Yen, T. Gujral, P. Sethupathy, C. A. Bradfield, S. M. Ronnekleiv-Kelly

This study identifies CDK7 as a therapeutic target in fibrolamellar carcinoma by showing its activation in FLC cells and efficacy of CDK7 inhibitors in patient-derived models.

bioRxiv · Apr 22, 2023 · PreprintCancer Biology

Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity

J. D. Kratz, S. Rehman, K. A. Johnson, A. A. Gillette, A. Sunil, P. F. Favreau, C. A. Pasch, D. Miller, L. C. Zarling, A. H. Yeung, L. Clipson, S. J. Anderson, A. K. DeZeeuw, C. M. Sprackling, K. K. Lemmon, , D. A. Deming

The paper evaluates individual patient-derived cancer organoids using optical metabolic imaging to predict therapeutic response and identify subclonal populations and resistance mechanisms.

bioRxiv · Oct 15, 2021 · PreprintCancer Biology

Impact of baseline culture conditions of mouse-derived cancer organoids when determining therapeutic response and tumor heterogeneity

R. A. DeStefanis, A. M. Olson, A. K. DeZeeuw, A. A. Gillette, G. C. Sha, K. A. Johnson, J. D. Kratz, C. A. Pasch, L. Clipson, M. C. Skala, D. A. Deming

This study evaluates how baseline culture conditions affect therapeutic response and heterogeneity in mouse-derived cancer organoids, finding that initial size is the key factor influencing growth and response.

bioRxiv · Oct 12, 2021 · PreprintCancer Biology